- Home
- CDNA
CDNA
CareDx Inc.
as 01-03-2025 4:00pm EST
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.1B | IPO Year: | 2014 |
| Target Price: | $27.17 | AVG Volume (30 days): | 682.2K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.42 - $34.84 | Next Earning Date: | 02-26-2025 |
| Revenue: | $312,775,000 | Revenue Growth: | 5.26% |
| Revenue Growth (this year): | 19.85% | Revenue Growth (next year): | 11.34% |
Stock Insider Trading Activity of CareDx Inc. (CDNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Novack Jeffrey Adam | CDNA | Secretary and General Counsel | Dec 4 '24 | Sell | $26.00 | 1,917 | $49,842.00 | 110,237 | |
| Maag Peter | CDNA | Director | Nov 26 '24 | Sell | $25.00 | 5,000 | $125,000.00 | 330,024 | |
| Novack Jeffrey Adam | CDNA | Secretary and General Counsel | Nov 18 '24 | Sell | $22.73 | 6,757 | $149,828.81 | 110,237 |
Latest CareDx Inc. News
CDNA Breaking Stock News: Dive into CDNA Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
High Growth Tech Stocks in the United States
Business Wire
18 days ago
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
25 days ago
CareDx, TC BioPharm Collaborate to Use AlloCell Test for Achieve Trial
Business Wire
25 days ago
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
PR Newswire
25 days ago
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
Simply Wall St.
a month ago
Exploring High Growth Tech Stocks In The United States December 2024
Zacks
a month ago
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Insider Monkey
a month ago
Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA)
Compare CDNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDNA CareDx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.